Chrysin is a dietary supplement made from a plant compound in honey, bee propolis and passionflower, sold to people facing cancer. Its activity against cancer targets is real in laboratory dishes and in mice, but oral doses barely enter the blood. Gut enzymes tag it and return it to the bowel, the one tissue that meets it in meaningful amounts. That bowel-directed question stays open rather than answered. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 10–26 U/L (women), 10–33 U/L (men) | Detects liver-cell stress from the conjugation load |
| AST | 10–26 U/L | Pairs with ALT to separate liver from muscle origin |
| Total bilirubin | 0.3–1.0 mg/dL | Reflects the sugar-tagging capacity chrysin is taken to induce |
| eGFR | ≥ 90 mL/min/1.73 m² | Confirms clearance reserve for co-administered drugs |
| Absolute neutrophil count | 2.0–5.0 × 10⁹/L | Sets the safety margin before any chemotherapy cycle |
| Estradiol | 10–30 pg/mL (men), 50–200 pg/mL (premenopausal women, first half of cycle) | Tests whether any aromatase effect is actually delivered |
| Total testosterone | 600–900 ng/dL (men) | Completes the hormone picture alongside estradiol |
| hs-CRP | < 1.0 mg/L | Tracks the inflammatory background chrysin is claimed to lower |
| CEA | No established target for supplement monitoring; track change from the individual's own baseline | Provides a disease-activity reference point in colorectal disease |
Cadence: Liver, kidney and blood count panel at baseline, 4 weeks, 12 weeks, then every 3–6 months while dosing continues; hormone measures, where relevant, at 8 weeks and then every 6 months; counts before each cycle where chemotherapy runs alongside chrysin.